Who
Dennis M. Lanfear
President & CEO
Company insider
Files Form 4 as: President & CEO, Coherus Oncology; Director, Insmed.
In numbers
- Trades disclosed
- 118
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $17.2M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 7 May 2008
- Last trade
- 29 May 2026
- Last filed
- 2 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —450,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —500,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —125,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —402,500 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —402,500 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —450,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —400,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —450,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —500,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —500,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —125,000 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —402,500 | filing |
| 29 May 2026filed 2 Jun 2026 | CHRS Coherus Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code D | —402,500 | filing |
News
Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026CHRS · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Dennis M. Lanfear; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.